Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.1Last Year’s EPS
-1Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: -42.96%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Arcturus Therapeutics. While there were significant achievements such as the European approval of KOSTAIVE and progress in various clinical programs, these were offset by financial challenges including decreased revenue and increased net loss. The company's strong cash position and expected cash runway provide some reassurance.Company Guidance
During the Arcturus Therapeutics Fourth and Full Year 2024 Earnings Call, several key metrics and updates were shared. For the fiscal year ending December 31, 2024, the company reported revenues of $152.3 million, a decrease from $166.8 million in 2023, largely due to lower milestone achievements from the CSL agreement. However, revenues for the fourth quarter of 2024 amounted to $22.8 million. Operating expenses for 2024 were $248 million, up slightly from $245 million in 2023, with research and development expenses rising to $195.2 million. The company reported a net loss of $80.9 million for 2024. Importantly, Arcturus achieved a significant milestone with the European Commission's approval of KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine, and recorded a $28 million gross profit share from its sale. The company anticipates continued revenue from ongoing clinical programs and maintains a strong cash position of $293.9 million as of December 31, 2024, supporting a cash runway extending to the end of Q1 2027. Additionally, Arcturus is progressing with its pipeline, including a Phase I study of ARCT-2304 for H5N1 influenza and a Phase II study for ARCT-032 in cystic fibrosis, with key data readouts expected in 2025.European Commission Approval for KOSTAIVE
Arcturus Therapeutics received European Commission approval for KOSTAIVE, the world's first approved self-amplifying mRNA COVID-19 vaccine, covering all 27 EU member states and 3 additional European economic area countries.
Significant Gross Profit from KOSTAIVE
Arcturus' share of gross profit from the sale of KOSTAIVE during Q4 2024 was approximately $28 million, which will offset development costs.
Initiation of Phase I Study for ARCT-2304
Initiated a Phase I study of ARCT-2304, a self-amplifying mRNA vaccine candidate for H5N1, fully funded by BARDA with interim data expected in the second half of 2025.
Continued Progress in Cystic Fibrosis Program
Dosed the first participant in a Phase II study of ARCT-032 for cystic fibrosis, with interim data expected by the end of Q2 2025.
Strong Cash Position
Cash and cash equivalents were $293.9 million as of December 31, 2024, with a cash runway expected until the end of Q1 2027.
---
ARCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $15.97 | $14.55 | -8.89% |
| Nov 07, 2024 | $18.74 | $19.62 | +4.70% |
| Aug 05, 2024 | $19.79 | $19.83 | +0.20% |
| May 08, 2024 | $27.21 | $26.79 | -1.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arcturus Therapeutics (ARCT) report earnings?
Arcturus Therapeutics (ARCT) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Arcturus Therapeutics (ARCT) earnings time?
Arcturus Therapeutics (ARCT) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARCT EPS forecast?
ARCT EPS forecast for the fiscal quarter 2025 (Q1) is -1.1.
---
